Abstract
Metabolic syndrome is defined as a set of health risk factors that are associated with an increased chance of cardiovascular diseases and type 2 diabetes. These include abdominal obesity, hyperglycemia, impaired glucose tolerance, dyslipidemia, and hypertension. Interventions in metabolic syndrome include lifestyle interventions such as a healthy diet using functional foods together with increased physical activity to induce weight loss as the first aim of treatment. Nutraceuticals such as tocotrienols and tocopherols as members of the vitamin E family may be more targeted interventions. This review evaluates the effects of tocotrienols on the risk factors of metabolic syndrome using data from human, animal and in vitro studies. Tocotrienols improved lipid profiles and reduced atherosclerotic lesions, decreased blood glucose and glycated hemoglobin concentrations, normalized blood pressure, and inhibited adipogenesis. The differences in responses between tocopherols and tocotrienols in preventing obesity, diabetes, hypertension, artherosclerosis, ischemia, and inflammation suggest that different receptors or signaling mechanisms may be involved.
Keywords: Metabolic syndrome, tocotrienols, tocopherols, diabetes, hypertension, atherosclerosis, adipogenesis, artherosclarosis, chylomicrons, hepatocytes
Current Pharmaceutical Design
Title: Nutrapharmacology of Tocotrienols for Metabolic Syndrome
Volume: 17 Issue: 21
Author(s): Wong Weng-Yew and Lindsay Brown
Affiliation:
Keywords: Metabolic syndrome, tocotrienols, tocopherols, diabetes, hypertension, atherosclerosis, adipogenesis, artherosclarosis, chylomicrons, hepatocytes
Abstract: Metabolic syndrome is defined as a set of health risk factors that are associated with an increased chance of cardiovascular diseases and type 2 diabetes. These include abdominal obesity, hyperglycemia, impaired glucose tolerance, dyslipidemia, and hypertension. Interventions in metabolic syndrome include lifestyle interventions such as a healthy diet using functional foods together with increased physical activity to induce weight loss as the first aim of treatment. Nutraceuticals such as tocotrienols and tocopherols as members of the vitamin E family may be more targeted interventions. This review evaluates the effects of tocotrienols on the risk factors of metabolic syndrome using data from human, animal and in vitro studies. Tocotrienols improved lipid profiles and reduced atherosclerotic lesions, decreased blood glucose and glycated hemoglobin concentrations, normalized blood pressure, and inhibited adipogenesis. The differences in responses between tocopherols and tocotrienols in preventing obesity, diabetes, hypertension, artherosclerosis, ischemia, and inflammation suggest that different receptors or signaling mechanisms may be involved.
Export Options
About this article
Cite this article as:
Weng-Yew Wong and Brown Lindsay, Nutrapharmacology of Tocotrienols for Metabolic Syndrome, Current Pharmaceutical Design 2011; 17 (21) . https://dx.doi.org/10.2174/138161211796957445
DOI https://dx.doi.org/10.2174/138161211796957445 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: [Challenges on the Improvement of Global Maternal Health]
Current Women`s Health Reviews Snacks and Snacking: Impact on Health of the Consumers and Opportunities for its Improvement
Current Nutrition & Food Science Editorial [Hot topic: Current Topics in the Development of Radioligands for Positron-Emission Tomography Imaging (Guest Editors: Andrew G. Horti and Robert F. Dannals)]
Current Topics in Medicinal Chemistry Extensive Coronary Calcification: A Clinically Unrecognised Condition
Current Vascular Pharmacology Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors
Current Enzyme Inhibition The Evaluation and Utilization of Marine-derived Bioactive Compounds with Anti-obesity Effect
Current Medicinal Chemistry Subject Index to Volume 4
Current Topics in Medicinal Chemistry The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry Food Bioactives versus Drugs – Introduction
Current Pediatric Reviews Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot topic: Hypertension and Diabetes (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Ocular Application of Macrobiomolecules in Anti-Allergy and Anti- Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Current Vascular Pharmacology Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Current Medicinal Chemistry Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Defining Statistical Race and Phenotypic Race and Their Implications for Health Disparities
Current Pharmacogenomics and Personalized Medicine Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System
Current Neuropharmacology